Jeff Edelson, MD
Dr. Jeff Edelson has more than 30 years of clinical practice, research, development, and management experience. As Chief Medical Officer, he provides clinical and regulatory assistance with portfolio programs, plays a key role in the due diligence process, and leads selected teams and projects.
Dr. Edelson has served in senior clinical research and development roles for several pharmaceutical firms including SmithKline Beecham, GlaxoSmithKline, Aventis, and Johnson and Johnson Pharmaceutical Research and Development, where he was most recently Therapeutic Area Head of Novel Therapeutics. He has also served as Chief Medical Officer for several emerging biotechnology firms. He has experience developing products for pulmonary, immunology, neurology, supportive care, and therapeutic oncology therapeutic areas, spanning preclinical, translational, early, full development, and post-registrational phases of activity.
Dr. Edelson trained and earned certifications in medicine, internal medicine, and pulmonary/critical care medicine at the University of Toronto, Toronto, Canada. He began his academic career as research fellow and lecturer at the National Jewish Research Center/University of Colorado School of Medicine in Denver, Colorado, where he studied lung epithelial function. He was appointed assistant professor of medicine at the University of Toronto in 1988, where he served as a clinician-scientist, leading a research program in acute lung injury. For 12 years he served as a clinical adjunct associate professor of medicine at the University of Pennsylvania Paul F. Harron Jr. Lung Center. He chaired the research ethics board (IRB) and was subsequently appointed as the founding Director of Research at St. Michael’s Hospital in Toronto, Ontario.